Brooks Laboratories Ltd
BROOKSBrooks Laboratories Ltd
BROOKS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -18.51 | 5.60 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.26 | 6.38 | 0.53% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Brooks Laboratories Ltd. is a Contract Manufacturing Company. The Company manufacturers molecules in Injectables and Clavulanic Acid range in Tablets and Dry Syrups.
Peers
Compare with peersDivi's Laboratories Ltd
Syngene International Ltd
Aarti Pharmalabs Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 77.99 | 91.98 | 63.77 | 80.45 | 79.27 | |||||
Raw Materials | 51.77 | 66.28 | 47.45 | 56.59 | 96.41 | |||||
| Power & Fuel Cost | 2.70 | 3.99 | 3.23 | 1.73 | ||||||
| Employee Cost | 12.04 | 16.85 | 16.00 | 10.09 | ||||||
| Selling & Administrative Expenses | 6.21 | 8.57 | 6.21 | 4.05 | ||||||
| Operating & Other expenses | 4.01 | 9.75 | 20.04 | 24.93 | ||||||
EBITDA | 1.26 | -13.46 | -29.16 | -16.94 | -17.14 | |||||
| Depreciation/Amortization | 7.14 | 7.35 | 7.03 | 1.77 | 1.72 | |||||
| PBIT | -5.88 | -20.81 | -36.19 | -18.71 | -18.86 | |||||
| Interest & Other Items | 3.10 | 3.10 | 2.18 | 0.84 | 0.96 | |||||
| PBT | -8.98 | -23.91 | -38.37 | -19.55 | -19.82 | |||||
| Taxes & Other Items | 10.38 | -12.61 | -17.47 | 0.03 | 0.03 | |||||
| Net Income | -19.36 | -11.30 | -20.90 | -19.58 | -19.85 | |||||
| EPS | -7.76 | -4.53 | -8.38 | -7.65 | -7.56 | |||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Brooks Laboratories Ltd | -18.77 | 5.60 | — |
| Divi's Laboratories Ltd | 99.52 | 11.73 | 0.50% |
| Syngene International Ltd | 68.38 | 8.19 | 0.14% |
| Aarti Pharmalabs Ltd | 27.30 | 3.37 | 0.46% |
Price Comparison
Compare BROOKS with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Brooks Laboratories Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Business Cycle Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.8385% | Percentage of the fund’s portfolio invested in the stock 0.91% | Change in the portfolio weight of the stock over the last 3 months 0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/43 (-7) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
BROOKS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet Loss of Brooks Laboratories reported to Rs 3.96 crore in the quarter ended September 2024 as against net loss of Rs 1.64 crore during the previous quarter ended September 2023. Sales declined 14.51% to Rs 20.79 crore in the quarter ended September 2024 as against Rs 24.32 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales20.7924.32 -15 OPM %-16.40-4.52 - PBDT-3.53-1.20 -194 PBT-3.96-1.64 -141 NP-3.96-1.64 -141 Powered by Capital Market - Live
Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Brooks Laboratories announced that the 22th Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live
Brooks Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live
Net Loss of Brooks Laboratories reported to Rs 2.41 crore in the quarter ended June 2024 as against net loss of Rs 4.47 crore during the previous quarter ended June 2023. Sales rose 14.20% to Rs 17.93 crore in the quarter ended June 2024 as against Rs 15.70 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales17.9315.70 14 OPM %-10.71-24.90 - PBDT-2.01-4.03 50 PBT-2.41-4.47 46 NP-2.41-4.47 46 Powered by Capital Market - Live
Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Brooks Laboratories reports consolidated net loss of Rs 4.68 crore in the September 2022 quarter
Capital Trust Ltd leads gainers in ‘B’ group
Brooks Laboratories’ subsidiary gets marketing authorization in Germany for Meropenem
Raj Oil Mills Ltd leads gainers in ‘B’ group
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant